(055) Day 1, 3, 5 vs Day 1, 2, 3 Intermediate to High-dose Cytarabine for Acute Myeloid Leukemia Consolidation Therapy in Patients 60 Years of Age or Greater

Poster Abstract: Background/Rationale
Acute myeloid leukemia (AML) is a hematologic malignancy characterized by proliferation of the stem cell precursor cells of the myeloid lineage. Intensive treatment for AML includes induction therapy followed by consolidation therapy. One consolidation therapy that can be used is intermediate (iDAC) to high-dose cytarabine (HiDAC).The standard regimen of HiDAC, given on day 1, 3, and 5, was compared to the condensed regimen HiDAC, given on days 1, 2, and 3, by Jaramillo and colleagues. The study found that the condensed HiDAC regimen had a shorter time to hematologic recovery, lower rates of infection, shorter hospitalized stay without effecting survival when compared to the standard regimen, but patients greater than 60 years of age were excluded. Despite the exclusion of this patient population, many patients 60 years of age or greater at our institution receive iDAC/HiDAC consolidation treatment using the condensed regimen. We aim to assess the differences in clinical outcomes between the standard regimen of high to intermediate-dose cytarabineto the condensed regimenfor consolidation therapy for AML in patients 60 years of age or greater at University Hospitals Cleveland Medical Center (UHCMC).
Objectives
The primary objective of this study is to assess the difference in absolute neutrophil count (ANC) and platelet recovery. Secondary objectives include differences in pegfilgrastim administration practices, length of stay, efficacy, and incidence of febrile neutropenia between the two groups.
Methods
This is a single-center, retrospective chart review. Patients are included if they had a diagnosis of AML , 60 years of age or greater, ordered high-dose (3g/m2) to intermediate dose (500mg/m2 – 2.5g/m2) cytarabine while admitted at UHCMC between January 1, 2020 through September 1, 2023. The primary endpoint will be assessed with a hierarchical model using a cox proportional hazard, while the secondary endpoints of pegfilgrastim administration and efficacy will be assessed using descriptive analysis. The secondary endpoints of length of stay and febrile neutropenia will be assessed using a hierarchical model t-test and hierarchical logistic regression respectively.
Results
Results pending
Discussion/Conclusions
Conclusion and discussion pending
Disclosure of financial interest
The authors of this abstract do not have any financial interest to disclose

References (must also be included in final poster): 1. Pelcovits A, Niroula R. Acute Myeloid Leukemia: A Review. R I Med J (2013). 2020 Apr 1;103(3):38-40.
2. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994 Oct 6;331(14):896-903.
3. Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, et al. Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. Blood Cancer J. 2017 May 26;7(5):e564.
4. Sperr WR, Piribauer M, Wimazal F, Fonatsch C, Thalhammer-Scherrer R, Schwarzinger I, et al. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5). Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3965-71.